@belightcare: A similar medication on the market currently is Lequembi which is an infusion every two weeks.  In June 2021, the FDA granted accelerated approval to Aducanumab based on its ability to reduce amyloid plaques. However, the approval was controversial due to the mixed clinical trial results and the high cost of the drug. As a result of ongoing debates and reassessments of its clinical benefits, Aducanumab is no longer provided and has been pulled from the market. In addition to the concerns noted in the video and above, there is ongoing controversy about the cause of Alzheimer's disease. For many years, researchers pointed to amyloid plaques as the cause of Alzheimer's. However, a 2006 study, now under scrutiny for potentially falsified results, has sparked new discussions. Some now believe that amyloid plaques might actually be a response to another underlying cause of Alzheimer's, rather than the direct cause itself. There’s a lot to untangle, but we need to keep in mind that the world is looking at Alzheimers. That’s good news. Focus on the brain health strategies we talked about last month and if you need it, know that other treatments are becoming available. Let me know your thoughts! #dementia #caregiver #alzheimers #dementiaawareness #dementiacare #caregiver #alzheimerssucks #vasculardementia #frontotemporaldementia #lewybodydementia #alzheimersfight #alzheimersdisease #dementiasucks #dementiasupport #caregiversupport #caregivers

Adria Thompson

Open In TikTok:

Region: US

Saturday 06 July 2024 21:58:53 GMT